A5058642751- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Bladder and Urothelial Cancer Treatments
- PI3K/AKT/mTOR signaling in cancer
- Urinary and Genital Oncology Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Immune Cell Function and Interaction
- Chronic Lymphocytic Leukemia Research
- Melanoma and MAPK Pathways
- vaccines and immunoinformatics approaches
- Sarcoma Diagnosis and Treatment
- Cutaneous Melanoma Detection and Management
- Reproductive System and Pregnancy
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Vascular Tumors and Angiosarcomas
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Cancer Research and Treatments
- T-cell and B-cell Immunology
- Peptidase Inhibition and Analysis
- Multiple and Secondary Primary Cancers
- Economic and Financial Impacts of Cancer
Institut Català d'Oncologia
2017-2025
Institut Català d'Ornitologia
2018-2025
Duran i Reynals Hospital
2019-2024
Vall d'Hebron Hospital Universitari
2015-2023
Vall d'Hebron Institute of Oncology
2015-2023
Institut d'Investigació Biomédica de Bellvitge
2011-2022
Centro de Investigación Biomédica en Red de Cáncer
2018-2021
CIBBIM-Nanomedicine
2018-2020
Hebron University
2019
Institut Català de Traumatologia i Medicina de l'Esport
2019
Treatment with programmed death receptor-1 (PD-1) antibodies is associated high response rates in patients advanced melanoma. Reliable markers for early and outcome are still sparse. We evaluated 66 consecutive advanced/metastatic melanoma treated nivolumab or pembrolizumab between 2013 2014. The main objectives of this study were to investigate whether, first, serum lactate dehydrogenase (LDH) at baseline (normal vs above the upper limit normal) correlates overall survival (OS), and,...
Abstract Lessons Learned Ramucirumab plus pembrolizumab revealed no unexpected safety findings in patients with advanced or metastatic biliary tract cancer, which is consistent reports of other tumor cohorts within this phase Ia/b trial. did not demonstrate an improvement overall survival when compared historical controls biomarker unselected, heavily pretreated cancer. Patients programmed death-ligand 1 (PD-L1)-positive tumors had improved PD-L1-negative disease. Background Few treatment...
Background Reliable predictive imaging markers of response to immune checkpoint inhibitors are needed. Purpose To develop and validate a pretreatment CT-based radiomics signature predict in advanced solid tumors. Materials Methods In this retrospective study, was developed patients with tumors (including breast, cervix, gastrointestinal) treated anti-programmed cell death-1 or programmed death ligand-1 monotherapy from August 2012 May 2018 (cohort 1). This tested bladder lung cancer (cohorts...
Most hyperprogression disease (HPD) definitions are based on tumor growth rate (TGR). However, there is still no consensus how to evaluate this phenomenon.We investigated two independent cohorts of patients with advanced solid tumors treated in phase I trials (i) programmed cell death 1 (PD-1)/PD-L1 antibodies monotherapy or combination and (ii) targeted agents (TA) unapproved indications. A Response Evaluation Criteria Solid Tumors (RECIST) 1.1-based definition was developed. The primary...
<h3>Importance</h3> Clinical trial evidence used to support drug approval is typically the only information on benefits and harms that patients clinicians can use for decision-making when novel cancer therapies become available. Various evaluations have raised concern about uncertainty surrounding these data, a systematic investigation of available treatment outcomes drugs approved by US Food Drug Administration (FDA) warranted. <h3>Objective</h3> To describe clinical data at time FDA all...
Background OX40 is a costimulatory receptor upregulated on antigen-activated T cells and constitutively expressed regulatory (Tregs). INCAGN01949, fully human immunoglobulin G1κ anti-OX40 agonist monoclonal antibody, was designed to promote tumor-specific immunity by effector T-cell activation Fcγ receptor-mediated Treg depletion. This first-in-human study conducted determine the safety, tolerability, preliminary efficacy of INCAGN01949. Methods Phase I/II, open-label, non-randomized,...
Abstract Purpose: Personalized vaccines targeting multiple neoantigens (nAgs) are a promising strategy for eliciting diversified antitumor T-cell response to overcome tumor heterogeneity. NOUS-PEV is vector-based personalized vaccine, expressing 60 nAgs and consists of priming with nonhuman Great Ape Adenoviral vector (GAd20) followed by boosts Modified Vaccinia Ankara. Here, we report data phase Ib trial in combination pembrolizumab treatment-naïve patients metastatic melanoma...
Solitary Fibrous Tumour (SFT) is a rare soft tissue neoplasm, described in several locations the body. It classified as intermediate malignant potential with low risk of metastasis and has tendency to recur after primary surgery.We performed prospective data collection patients SFT presented Royal Marsden Hospital from January December 2013, treated pazopanib first line. Demographics, anatomic sites, treatment survival outcomes were collected patients' electronic records.13 (54% females)...
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved treatment1. Yet, response rates still limited, tumour progression commonly occurs2. Soluble cell-bound factors in the microenvironment negatively affect immunity. Recently, growth differentiation factor 15 (GDF-15), a cytokine that is abundantly produced by many types, was shown to interfere antitumour response. In preclinical models,...
Background. Soft-tissue sarcomas (STS) are a heterogeneous group of diseases with lack effective treatments in most cases. Previous data suggest that continuous infusional ifosfamide regimens might improve cytotoxicity and tolerability compared to standard schedules. Methods. We retrospectively report the outcome 35 patients affected by STS treated 14-day regimen (1000 mg/m(2)/day) our institution. Predictive factors for toxicity were also explored. Results. Median age was 53 years. There 16...
9505 Background: Immune checkpoint inhibitors (ICI) are front-line standard-of-care treatment (tx) for advanced (unresectable or metastatic) melanoma. Despite recent advances in tx, a majority of patients (pts) do not achieve long-term benefit. Lifileucel, one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, potentially induces durable responses pts with melanoma previously treated ICI. This study evaluates lifileucel combined anti-PD-1 therapy Methods: IOV-COM-202...
Background: Anti-PD-1-based immunotherapy has improved outcomes in stage IIB to IV resected melanoma patients clinical trials. However, little is known about real-world outcomes, prognostic factors and patterns of relapse. Methods: This a retrospective multicenter observational study including with treated subsequent anti-PD-1-based adjuvant immunotherapy. Data on demographic characteristics, delivered treatment, factors, time pattern relapse were collected. Results: We included 245 from...
Background CV8102, a toll-like receptor 7/8 and RIG I agonist, has demonstrated antitumor immune responses in preclinical studies. We investigated intratumoral (IT) administration of CV8102 patients with anti-programmed cell death protein-1 (PD-1) therapy-naïve or anti-PD-1 therapy-refractory cutaneous melanoma (cMEL) advanced squamous carcinoma, head neck carcinoma adenoid cystic carcinoma. Methods This open-label, cohort-based, phase dose escalation study aimed to establish the maximum...
e15155 Background: High-dose (HD) IL-2 is approved for patients with melanoma and renal cell carcinoma but associated significant toxicity, given only in an inpatient setting. RO6874281 a novel, monomeric, bispecific IL-2v immunocytokine that completely lacks binding to IL-2Rα, retains IL-2Rβγ binding, shows pM affinity FAP on tumor-associated fibroblasts. While the domain activates IL-2R expressing immune effector CD8 T NK cells independent of FAP-binding, targeting via results retention...
Abstract Purpose: To characterize safety and tolerability of the selective PI3Kβ inhibitor AZD8186, identify a recommended phase II dose (RP2D), assess preliminary efficacy in combination with abiraterone acetate or vistusertib. Patients Methods: This I open-label study included patients advanced solid tumors, particularly prostate cancer, triple-negative breast squamous non–small cell lung cancer. The comprised four arms: (i) AZD8186 monotherapy finding; (ii) expansion; (iii)...